Bharat Biotech's Covaxin approved for phase 2/3 trials on children

The Drugs Controller General of India (DGCI) has approved Bharat Biotech's COVID-19 vaccine Covaxin for phase II/III clinical trial on those aged between two to 18 years. The trial will take place in 525 subjects at various sites, including AIIMS, Delhi, AIIMS, Patna and Meditrina Institute of Medical Sciences, Nagpur. In the trial, the vaccine will be given by intramuscular route in two doses at day 0 and day 28.

The Drugs Controller General of India (DGCI) has approved Bharat Biotech's COVID-19 vaccine Covaxin for phase II/III clinical trial on those aged between two to 18 years. The trial will take place in 525 subjects at various sites, including AIIMS, Delhi, AIIMS, Patna and Meditrina Institute of Medical Sciences, Nagpur. In the trial, the vaccine will be given by intramuscular route in two doses at day 0 and day 28. May 13, 2021 at 10:41AM https://ift.tt/3obZKyA